Latest astrocytoma Stories
TUSTIN, Calif., Feb. 11 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc.
Missing, mutated genes occur simultaneously in unique set of pediatric brain tumors.
There was no substantial change in brain tumor incidence among adults 5 to 10 years after cell phone usage sharply increased.
TUSTIN, Calif., Dec. 2 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM) today reported completion of patient enrollment in a dose confirmation and dosimetry trial of CotaraÂ® in patients with relapsed glioblastoma multiforme (GBM), the deadliest form of brain cancer.
BOSTON, Mass. and TUSTIN, Calif., Sept. 2 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc.
Malignant brain tumors often fail to respond to promising new medication. Researchers in Heidelberg have discovered a mechanism and a tumor marker for the development of this resistance.
A new technology involving the fusion of four different types of images into a 3-D map of a patientâ€™s brain has helped University of Cincinnati (UC) specialists successfully remove a fist-sized tumor from the brain of an Indiana woman.
- Dosimetry Study Results Show Greater Than 300-Fold More Radiation Delivered to Tumor as Compared to Other Normal Organs - - All Patients in the First Two Cohorts Have Met or Exceeded the Expected Median Survival Time for Recurrent GBM Patients - TORONTO and TUSTIN, Calif., June 16 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc.
Drummer for 'Loose Chains' joins researchers, physicians, neurosurgeons and other brain tumor survivors June 13 at Cedars-Sinai Medical Center LOS ANGELES, June 1 /PRNewswire/ -- It is not uncommon for musicians to have to work around scheduling conflicts, but Eddie Cleland, drummer for "Loose Chains" and two other bands, had to adjust his calendar to accommodate brain tumor surgery, which was performed by Keith Black, M.D., chairman of the Department of Neurosurgery at Cedars-Sinai Medical...
--Data from Ongoing Glioblastoma Dosimetry Trial Accepted for Oral Presentation at 2009 Society of Nuclear Medicine Annual Meeting -- --Over 65 Recurrent GBM Patients in Phase I and Phase II Clinical Trials Have Received Cotara to Date, with a Good Safety Profile and Longer-Term Survivors Seen in All Studies-- TUSTIN, Calif., May 28 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc.
- totally perplexed and mixed up.